Thursday, December 19, 2019 1:42:15 PM
“AbbVie Inc. ABBV announced that the European Commission has granted approval to its JAK inhibitor, Rinvoq (upadacitinib) for the treatment of moderate-to-severe rheumatoid arthritis (“RA”) in patients who experience inadequate response or are intolerant to disease-modifying anti-rheumatic drugs (DMARDs). The drug is approved as a monotherapy or in combination with methotrexate in this patient population.
Please note that the JAK inhibitor had received approval for a similar indication in the United States in August and the early uptake trends of the drug have been encouraging.Rinvoq has generated sales of $14 million in the third quarter since its approval.
Shares of AbbVie have gained 14% in the past six months compared with the industry’s increase of 6%.
The approval for Rinvoq in Europe was based on encouraging data from the phase III SELECT program, which evaluated more than 4000 patients across five phase III studies on RA. In all studies, the drug met every primary and secondary endpoint. Data from the studies under the SELECT program demonstrated that Rinvoq alone or in combination with conventional synthetic DMARDs improved rates of low disease activity and clinical remission in RA patients compared to placebo, MTX or AbbVie’s blockbuster inflammatory drug, Humira (adalimumab).
Humira is the primary revenue generator for AbbVie with global sales of more than $14 billion in the first nine months of 2019. However, the drug’s sales declined significantly in Europe due to the launch of several biosimilars last year from companies including Amgen AMGN, Biogen BIIB and Novartis NVS. Moreover, the drug is set to lose patent protection in the United States, beginning 2023. A similar decline in U.S. sales for the drug will significantly dent AbbVie’s revenues going forward.
We expect Rinvoq and AbbVie’s another new inflammation drug, Skyrizi, to partially offset lost sales for Humira over the long term. However, Humira is approved for 10 different inflammatory indications. AbbVie’s efforts to expand labels of Skyrizi and Rinvoq will further reduce the impact of patent loss for Humira on its revenues, if successful.
In a separate event, the company has reportedly entered into an agreement with the pan-Canadian Pharmaceutical Alliance for the commercialization of Venclexta in combination with J&J’s Rituxan (rituximab) as a treatment for chronic lymphocytic leukemia in second or later-line setting.”
https://finance.yahoo.com/news/abbvies-jak-inhibitor-rinvoq-receives-150103062.html
Recent ABBV News
- Empowering Women Entrepreneurs: 2024 BOTOX® (onabotulinumtoxinA) Cosmetic Grant Recipients Kick Off Crowdfunding Campaigns • PR Newswire (US) • 09/24/2024 12:00:00 PM
- AbbVie Receives Positive CHMP Opinion for Mirvetuximab Soravtansine (ELAHERE®) for the Treatment of Certain Adult Ovarian Cancer • PR Newswire (US) • 09/20/2024 11:32:00 AM
- Allergan Aesthetics Launches BOTOX® Cosmetic (onabotulinumtoxinA) for Masseter Muscle Prominence (MMP) in Adults in China • PR Newswire (US) • 09/11/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/10/2024 07:30:45 PM
- Health Canada Approves AbbVie's CONSTELLA® (linaclotide) for the Treatment of Functional Constipation in Pediatric Patients 6 to 17 Years of Age • PR Newswire (Canada) • 09/10/2024 11:00:00 AM
- AbbVie reçoit l'approbation de Santé Canada pour l'emploi de CONSTELLA® (linaclotide) dans le traitement de la constipation fonctionnelle chez les enfants âgés de 6 à 17 ans • PR Newswire (Canada) • 09/10/2024 11:00:00 AM
- AbbVie Showcases Advancement of Solid Tumor Pipeline at ESMO 2024, with New Data in Tumor Types with High Unmet Needs • PR Newswire (US) • 09/09/2024 01:00:00 PM
- AbbVie Declares Quarterly Dividend • PR Newswire (US) • 09/06/2024 02:13:00 PM
- AbbVie reçoit une recommandation favorable de la part de l'Agence des médicaments du Canada pour le remboursement de VRAYLAR® (cariprazine) dans le traitement de la schizophrénie • PR Newswire (Canada) • 09/04/2024 12:00:00 PM
- AbbVie's VRAYLAR® (cariprazine) Receives Positive Reimbursement Recommendation by Canada's Drug Agency for the Treatment of Schizophrenia • PR Newswire (Canada) • 09/04/2024 12:00:00 PM
- AbbVie Awards Scholarships to 45 U.S. Students Living With Chronic Immune-Mediated Diseases • PR Newswire (US) • 08/27/2024 12:15:00 PM
- SkinMedica® Revolutionizes Skin Hydration with the Introduction of HA5® Hydra Collagen Replenish + Restore Hydrator • PR Newswire (US) • 08/27/2024 12:05:00 PM
- European Commission Grants Second Indication Approval for TEPKINLY® (epcoritamab) for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma • PR Newswire (US) • 08/19/2024 06:05:00 PM
- AbbVie annonce les premiers remboursements provinciaux, en Ontario et au Québec, d'EPKINLY(MC) (epcoritamab) administré par voie sous-cutanée pour le traitement du lymphome diffus à grandes cellules B en vertu d'un nouveau processus d'accès rapide • PR Newswire (Canada) • 08/15/2024 01:14:00 PM
- AbbVie Announces Ontario and Quebec are First Provinces to Reimburse Subcutaneous EPKINLY™ (epcoritamab) for the Treatment of Diffuse Large B-Cell Lymphoma Under New Early Access Process • PR Newswire (Canada) • 08/15/2024 01:13:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 08/14/2024 08:09:27 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/08/2024 09:40:43 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/07/2024 08:22:53 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/07/2024 07:00:51 PM
- AbbVie Completes Acquisition of Cerevel Therapeutics • PR Newswire (US) • 08/01/2024 12:23:00 PM
- Allergan Aesthetics Celebrates the Second Annual JUVÉDERM® Day • PR Newswire (US) • 07/30/2024 12:00:00 PM
- Toyota Reports Another Global Production Decline, Delta Sues CrowdStrike, Meta Launches AI Studio for Custom Chatbots • IH Market News • 07/30/2024 10:00:51 AM
- Alector Presents Baseline Characteristics for INVOKE-2 Phase 2 Clinical Trial of AL002 at the Alzheimer's Association International Conference® 2024 (AAIC®) • GlobeNewswire Inc. • 07/28/2024 12:05:00 PM
- AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis • PR Newswire (US) • 07/26/2024 06:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/25/2024 11:41:17 AM
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM